Tremelimumab, a monoclonal anti-CTLA4 antibody was assessed in a phase II multi-center clinical trial including 20 patients with advanced HCC from hepatitis C viral etiology. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.